Tirzepatide vs Semaglutide
Dual Agonist vs Single Agonist — The Science Behind the Brand Names
Forget the brand names for a moment. Semaglutide (Ozempic/Wegovy) activates one receptor. Tirzepatide (Mounjaro/Zepbound) activates two. That structural difference drives measurably better weight loss outcomes in head-to-head trials and explains why the mechanism comparison matters to anyone choosing between them.
Mechanism of Action: Side by Side
- →Targets GLP-1 receptors only
- →Mimics incretin hormone released after eating
- →Stimulates insulin secretion (glucose-dependent)
- →Suppresses glucagon → lowers hepatic glucose output
- →Acts on hypothalamus to reduce appetite
- →Slows gastric emptying → prolongs satiety
- →Half-life ≈7 days (once-weekly dosing)
- →Targets both GIP and GLP-1 receptors simultaneously
- →GIP agonism enhances insulin sensitivity in adipose tissue
- →GIP activity may reduce GI side effects vs GLP-1 alone
- →Dual signalling drives deeper weight loss in trials
- →Also suppresses appetite via hypothalamic pathways
- →Slows gastric emptying similarly to semaglutide
- →Half-life ≈5 days (once-weekly dosing)
Head-to-Head Comparison
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1 only | GIP + GLP-1Best |
| Brand names (injectable) | Ozempic (T2D), Wegovy (obesity) | Mounjaro (T2D), Zepbound (obesity) |
| FDA approval (obesity) | Wegovy — June 2021 | Zepbound — November 2023 |
| Max dose | 2.4 mg weekly (Wegovy) | 15 mg weekly |
| Weight loss — Phase 3 | ~15% (STEP-1, Wegovy 2.4 mg) | ~21% (SURMOUNT-1, 15 mg) |
| HbA1c reduction | ~1.8–2.2% | ~2.0–2.3% |
| Nausea incidence | ~44% (Wegovy dose) | ~31% (15 mg) |
| CV outcome trial | SUSTAIN-6 / SELECT (positive) | SURMOUNT-MMO (ongoing) |
| Oral formulation | Yes (Rybelsus, T2D only) | Oral in development |
| Compounded available | Yes (FDA shortage list, check date) | Limited — check FDA status |
Weight Loss: The Numbers
Which Drug Is Right for You?
For maximum weight loss in people with obesity or overweight, tirzepatide 15 mg shows greater efficacy than semaglutide 2.4 mg in both individual trials and the 2025 head-to-head SURPASS-STEP trial. If primary weight loss is the goal and your prescriber has no contraindications, tirzepatide is the evidence-based choice.
Semaglutide has longer real-world data (approved 2017 for T2D, 2021 for obesity), a proven cardiovascular outcome trial (SUSTAIN-6, SELECT), and an oral formulation (Rybelsus). If cardiovascular risk reduction is a priority alongside glycaemic control, semaglutide's SELECT outcome data is currently more established than tirzepatide's (SURMOUNT-MMO pending).
GI tolerability: some clinicians note tirzepatide causes less nausea in practice due to GIP modulating GLP-1 side effects, though both drugs are well-tolerated by most patients when dosed with the standard slow escalation.
Choose Based on Your Goal
Maximum weight loss
Tirzepatide 15 mg shows ~20.9% mean weight loss in SURMOUNT-1, vs ~14.9% for semaglutide in STEP-1.
Established CV data
Semaglutide has two positive cardiovascular outcome trials (SUSTAIN-6, SELECT). Tirzepatide's MMO trial is ongoing.
Oral formulation now
Rybelsus (oral semaglutide, 3–14 mg) is available for T2D. No approved oral tirzepatide exists yet.
Lower GI side effects
Tirzepatide's SURMOUNT-1 reported ~31% nausea vs ~44% for semaglutide at weight-loss doses in STEP-1.
Insurance / cost
Brand costs are comparable ($900–1,100/month uninsured). Coverage varies. Compounded semaglutide is more widely available historically.
T2D + weight management combo
Both are FDA-approved for type 2 diabetes with weight benefits. Discuss with your endocrinologist which fits your full metabolic profile.
Tirzepatide vs Semaglutide: Frequently Asked Questions
By weight loss efficacy, yes. Tirzepatide 15 mg achieved ~20.9% mean weight loss in SURMOUNT-1 vs ~14.9% for semaglutide 2.4 mg in STEP-1. The 2025 SURPASS-STEP head-to-head trial confirmed tirzepatide's superiority for weight reduction. For cardiovascular outcomes, semaglutide has stronger published trial data (SELECT, 2023).
Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors. Ozempic (semaglutide) targets GLP-1 only. Mounjaro is approved for type 2 diabetes; Zepbound (same molecule) is approved for obesity. Ozempic is approved for type 2 diabetes; Wegovy (same molecule, higher dose) is approved for obesity.
Yes, with prescriber guidance. There is no mandatory washout period between the two. Common practice is to start tirzepatide at the lowest dose (2.5 mg) regardless of the semaglutide dose previously used, then escalate normally. Track both drugs in Shotlee so your prescriber can compare your response to each.
Both cause similar GI side effects (nausea, vomiting, constipation, diarrhoea). Clinical trial data suggests slightly lower nausea rates with tirzepatide (31% vs 44% at weight-loss doses). Individual tolerance varies considerably. Track your side effects in Shotlee to identify patterns.
Insurance coverage varies widely. For obesity (without type 2 diabetes): Zepbound and Wegovy have the broadest obesity coverage but many plans still exclude them. For type 2 diabetes: Mounjaro and Ozempic have better coverage. Manufacturer savings programs (Lilly's and Novo's) can reduce costs for eligible patients.
Track Whichever GLP-1 You Use
Shotlee supports both semaglutide and tirzepatide dose logging, weight tracking, and side effect recording — completely free.
📚References & sources
Latest on Tirzepatide
Alli Weight Loss Pill: FDA Flags Serious Kidney Risks
The Food and Drug Administration (FDA) has issued a new warning regarding potential serious kidney complications associated with Alli, the sole over-the-counter weight loss medication available in the United States. The drug's label has been updated to reflect these risks, urging caution for consumers.
8 min read
Beyond Weight Loss: How GLP-1s Impact Your Blood Pressure
GLP-1 receptor agonists, known for their role in diabetes and weight management, are increasingly recognized for their broader health benefits, including effects on blood pressure. This article delves into how these medications work, their impact on cardiovascular health, and whether they are safe for individuals with hypertension.
8 min read
Wegovy Pill Arrives in the UK: A New Era for Weight Management?
The UK has officially approved a pill version of the popular Wegovy weight-loss drug, marking a significant advancement in accessible obesity treatment. This development offers a convenient alternative to weekly injections for many.
6 min read